Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03289143
Registration number
NCT03289143
Ethics application status
Date submitted
18/09/2017
Date registered
20/09/2017
Date last updated
16/03/2022
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
Query!
Scientific title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease
Query!
Secondary ID [1]
0
0
2017-001800-31
Query!
Secondary ID [2]
0
0
GN39763
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Semorinemab
Treatment: Drugs - Placebo
Treatment: Drugs - [18F]GTP1
Experimental: Dose 1 Semorinemab -
Experimental: Dose 2 Semorinemab -
Experimental: Dose 3 Semorinemab -
Placebo Comparator: Placebo -
Treatment: Drugs: Semorinemab
Participants will receive Semorinemab intravenously (IV).
Treatment: Drugs: Placebo
Matching placebo doses of Semorinemab given intravenously (IV).
Treatment: Drugs: [18F]GTP1
[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline on the CDR-SB
Query!
Assessment method [1]
0
0
The Clinical Dementia Rating-Sum of Boxes (CDR-SB) rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment = 0, questionable impairment = 0.5 and mild, moderate and severe impairment = 1, 2 and 3 respectively. The score range is from 0 to 18 with a high score indicating a high disease severity. The difference in mean change from Baseline to Week 73 between Semorinemab doses and Placebo treated participants was estimated. The difference in mean change from Baseline to Week 73 between Semorinemab doses and Placebo treated participants was estimated.
Query!
Timepoint [1]
0
0
Baseline and 73 Weeks
Query!
Primary outcome [2]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [2]
0
0
Percentage of participants with at least one adverse event
Query!
Timepoint [2]
0
0
Up to the data cutoff date 15 January 2021 (up to approximately 39 months)
Query!
Primary outcome [3]
0
0
Change From Baseline on the C-SSRS
Query!
Assessment method [3]
0
0
Categories are as defined in the Classification Algorithm for Suicide Assessment (CASA) based on the Columbia Suicide Severity Rating Scale (C-SSRS) questionnaire. SI1: Passive category is "Wish to be dead", SI2: Active-Nonspecific (no method, intent or plan), SI3: Active-Method, but no intent or Plan, SI4: Active-Method and intent, but no plan in C-SSRS. The worst post-baseline suicidal ideation is the highest across post-baseline visits, with highest as SI5 and lowest as SI1. Percentages are based on the total number of subjects in a treatment group. Baseline is the last observation prior to initiation of study drug.
Query!
Timepoint [3]
0
0
Baseline to data cutoff date 15 January 2021 (up to approximately 39 months)
Query!
Primary outcome [4]
0
0
Other Abnormal MRI Findings
Query!
Assessment method [4]
0
0
Other abnormal MRI findings by visit. For the Double Blind Period, baseline is defined as last results prior to initiation of study drug. For the Open Label Extension Period, baseline is defined as last results prior to entering the open label period.
Query!
Timepoint [4]
0
0
Baseline, Week 9, Week 49, Week 73, Study Treatment Discontinuation, and Week 89
Query!
Secondary outcome [1]
0
0
Change From Baseline on the Repeatable Battery for Assessment of Neuropsychological Status (RBANS)
Query!
Assessment method [1]
0
0
The RBANS is a validated neuropsychological assessment has been shown to be a useful tool in both clinical and research settings. The RBANS consists of ten subtests that are combined to provide five indices, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, and delayed memory). Scores range from 40 to 160 and a higher score indicates better cognitive functioning. A decrease in the outcome measure from baseline corresponds to disease worsening. The difference in mean change from Baseline to Week 73 between Semorinemab doses and Placebo treated participants was estimated.
Query!
Timepoint [1]
0
0
Baseline and 73 weeks
Query!
Secondary outcome [2]
0
0
Change From Baseline on the Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog-13) Subscale Score
Query!
Assessment method [2]
0
0
The ADAS-Cog-13 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The ADAS-Cog-13 is the ADAS-Cog-11 with 2 further items: delayed word recall and total digit cancellation. The score range for ADAS-Cog-13 is from 0 to 85 with high scores representing severe dysfunction. The difference in mean change from Baseline to Week 73 between Semorinemab doses and Placebo treated participants was estimated.
Query!
Timepoint [2]
0
0
Baseline and 73 weeks
Query!
Secondary outcome [3]
0
0
Change From Baseline on the Amsterdam Instrumental Activity of Daily Living (iADL) Questionnaire
Query!
Assessment method [3]
0
0
The Amsterdam iADL questionnaire is an informant-based instrument for measuring iADL problems in participants with dementia. This instrument consists of 70 items, scored on a 5-point scale, that uses item response theory for scoring. Items presented to the informant are tailored to responses to earlier items; thus each administration of the Amsterdam iADL may consist of less than the total of 70 items. The resulting score ranges from 20 to 80 with lower scores indicating poorer performance. A decrease in the outcome measure from baseline corresponds to disease worsening. The difference in mean change from Baseline to Week 73 between Semorinemab doses and Placebo treated participants was estimated.
Query!
Timepoint [3]
0
0
Baseline and 73 weeks
Query!
Secondary outcome [4]
0
0
Change From Baseline on the Alzheimer's Disease Cooperative Study Group-Activities of Daily Living Inventory
Query!
Assessment method [4]
0
0
The ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) is the scale most widely used to assess functional outcomes in participants with AD. The ADCS-ADL covers both basic ADL (e.g., eating and toileting) and more complex 'instrumental' ADL or iADL (e.g., using the telephone, managing finances and preparing a meal). The ADCS-ADL consists of 23 questions with a score range of 0 to 78 where a higher score represents better function. The difference in mean change from Baseline to Week 73 between Semorinemab doses and Placebo treated participants was estimated.
Query!
Timepoint [4]
0
0
Baseline and 73 weeks
Query!
Secondary outcome [5]
0
0
Serum Concentrations of Semorinemab at Specified Timepoints
Query!
Assessment method [5]
0
0
Serum concentrations of Semorinemab at specified timepoints.
Query!
Timepoint [5]
0
0
Up to 109 weeks
Query!
Secondary outcome [6]
0
0
Presence of Anti-drug Antibodies During the Study Relative to Their Presence at Baseline
Query!
Assessment method [6]
0
0
Presence of anti-drug antibodies during the study relative to their presence at baseline.
Query!
Timepoint [6]
0
0
Up to 109 weeks
Query!
Eligibility
Key inclusion criteria
Inclusion criteria
- Age between 50 and 80 years
- National Institute on Aging/Alzheimer's Association core clinical criteria for
probable Alzheimer's disease (AD) dementia or mild cognitive impairment (prodromal AD)
- Evidence of the AD pathological process, by a positive amyloid assessment either on
cerebrospinal fluid Aß1-42 OR amyloid positron emission tomography (PET) scan.
Historical amyloid PET scans may be accepted in some cases
- Mild AD symptomatology, as defined by a screening Mini-Mental State Examination score
of >= 20 points and Clinical Dementia Rating (CDR) -Global Score of 0.5 or 1
- Abnormal memory function at screening
- Availability of a person with sufficient contact with the participant to be able to
provide accurate information on the participant's cognitive and functional ability
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria
- Pregnant or breastfeeding
- Inability to tolerate magnetic resonance imaging (MRI) procedures or contraindication
to MRI
- Contraindications to both PET imaging and lumbar dural puncture (must be able to
undergo at least one of these procedures to be eligible)
- Residence in a skilled nursing facility
- Any serious medical condition or abnormality in clinical laboratory tests that remains
abnormal on retest and, in the investigator's judgment, precludes the patient's safe
participation in and completion of the study, or bias the assessment of the clinical
or mental status of the participant to a significant degree
- Any evidence of a condition other than AD that may affect cognition
- Alcohol or substance abuse within the past 2 years
- Use of any experimental therapy within 90 days or 5 half-lives prior to screening,
whichever is greater and any passive immunotherapy (immunoglobulin) against tau,
except use of RO7105705 in Genentech Study GN39058, as long as the last dose was at
least 90 days prior to screening
- Use of any passive immunotherapy (immunoglobulin) against Aß, unless the last dose was
at least 1 year prior to screening and any active immunotherapy (vaccine) that is
under evaluation to prevent or postpone cognitive decline
- Any previous treatment with medications specifically intended to treat Parkinsonian
symptoms or any other neurodegenerative disorder within 1 year of screening
- Systemic immunosuppressive therapy within 12 months of screening through the entire
study period
- Typical antipsychotic or neuroleptic medication within 6 months of screening
- Daily treatment with any of the following classes of medication, except for
intermittent short-term use, which is permitted except within 2 days or 5 half-lives
(whichever is longer) prior to any COA: atypical antipsychotics, opiates or opioids,
benzodiazepines, barbiturates, hypnotics, or any medication with clinically
significant centrally-acting antihistamine or anticholinergic activity
- Stimulant medications, unless the dose has been stable within the 6 months prior to
screening and is expected to be stable throughout the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/10/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
15/01/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
457
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
St Vincents Medical Centre - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Southern Neurology - Kogarah
Query!
Recruitment hospital [3]
0
0
Queensland University of Technology - Mermaid Waters
Query!
Recruitment hospital [4]
0
0
Eastern Clinical Research Unit; Pharmacy - Box Hill
Query!
Recruitment hospital [5]
0
0
HammondCare Aged Psychiatry Clinical Trials - Malvern
Query!
Recruitment hospital [6]
0
0
The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit - Melbourne
Query!
Recruitment hospital [7]
0
0
Neuro Trials Victoria - Noble Park
Query!
Recruitment hospital [8]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
4218 - Mermaid Waters
Query!
Recruitment postcode(s) [4]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [5]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [6]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [7]
0
0
3174 - Noble Park
Query!
Recruitment postcode(s) [8]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maine
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Rhode Island
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Vermont
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Brussel
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Kortrijk
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Leuven
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Roeselare
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Ontario
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Quebec
Query!
Country [24]
0
0
Denmark
Query!
State/province [24]
0
0
Aalborg
Query!
Country [25]
0
0
Denmark
Query!
State/province [25]
0
0
Vejle
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Bordeaux
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Bron
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Lille
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Marseille
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Montpellier
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Paris
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Rennes
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Strasbourg
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Toulouse
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Villeurbanne
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Bayreuth
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Berlin
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Günzburg
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Hannover
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
München
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Siegen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Tubingen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Ulm
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Lazio
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Liguria
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Lombardia
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Molise
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Puglia
Query!
Country [49]
0
0
Netherlands
Query!
State/province [49]
0
0
'S Hertogenbosch
Query!
Country [50]
0
0
Netherlands
Query!
State/province [50]
0
0
Amsterdam
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Bialystok
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Bydgoszcz
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Katowice
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Krakow
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Poznan
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Siemianowice Slaskie
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Sopot
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Szczecin
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Warszawa
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Wroclaw
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Barcelona
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Guipuzcoa
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Navarra
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Palencia
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Vizcaya
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Albacete
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Cordoba
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Madrid
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Sevilla
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Valencia
Query!
Country [71]
0
0
Sweden
Query!
State/province [71]
0
0
Jönköping
Query!
Country [72]
0
0
Sweden
Query!
State/province [72]
0
0
Kalmar
Query!
Country [73]
0
0
Sweden
Query!
State/province [73]
0
0
Malmö
Query!
Country [74]
0
0
Sweden
Query!
State/province [74]
0
0
Mölndal
Query!
Country [75]
0
0
Sweden
Query!
State/province [75]
0
0
Stockholm
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Glasgow
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
London
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the
efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's
disease. An optional 96-week open-label extension period was available to participants who
completed the double-blind treatment period and who, in the judgment of the investigator,
would potentially benefit from open-label Semorinemab treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03289143
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Genentech, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03289143
Download to PDF